ArticleProceedings of the National Academy of Sciences of the United States of America2015
A set of NF-κB-regulated microRNAs induces acquired TRAIL resistance in lung cancer.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 74 citations in OpenAlex.
- Targeting the NF-κB Pathway in Cancer: Mechanisms, Resistance, and Therapeutic Potential Across Tumor Types.Pharmaceuticals (Basel, Switzerland) · 2025Review
- A seven-LncRNA signature for prognosis prediction of patients with lung squamous cell carcinoma through tumor immune escape.Frontiers in oncology · 2025Article
- Review
- Extracellular vesicle-encapsulated miR-30c-5p reduces aging-related liver fibrosis.Aging cell · 2024Article
- Article
- Pre-Protection and Mechanism of Crude Extracts fromAnimals : an open access journal from MDPI · 2023Article
- Apoptosis evasion via long non-coding RNAs in colorectal cancer.Cancer cell international · 2022Review
- Tumor-targeted miRNA nanomedicine for overcoming challenges in immunity and therapeutic resistance.Nanomedicine (London, England) · 2022Review
- Kaempferol sensitizes tumor necrosis factor-related apoptosis-inducing ligand-resistance chronic myelogenous leukemia cells to apoptosis.Molecular biology reports · 2022Article
- EV-Mediated Chemoresistance in the Tumor Microenvironment: Is NF-κB a Player?Frontiers in oncology · 2022Review
- Molecular Mechanisms of Chemoresistance Induced by Cisplatin in NSCLC Cancer Therapy.International journal of molecular sciences · 2021Review
- The lncRNA CASC2 Modulates Hepatocellular Carcinoma Cell Sensitivity and Resistance to TRAIL Through Apoptotic and Non-Apoptotic Signaling.Frontiers in oncology · 2021Article
- Harnessing TRAIL-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges.Frontiers in immunology · 2021Review
- TRAIL receptor-induced features of epithelial-to-mesenchymal transition increase tumour phenotypic heterogeneity: potential cell survival mechanisms.British journal of cancer · 2021Review
- Review
- PD-L1 Under Regulation of miR-429 Influences the Sensitivity of Gastric Cancer Cells to TRAIL by Binding of EGFR.Frontiers in oncology · 2020Article
- PD173074 blocks G1/S transition via CUL3-mediated ubiquitin protease in HepG2 and Hep3B cells.PloS one · 2020Article
- Crosstalk of MicroRNAs and Oxidative Stress in the Pathogenesis of Cancer.Oxidative medicine and cellular longevity · 2020Review
- MicroRNA-18a promotes cancer progression through SMG1 suppression and mTOR pathway activation in nasopharyngeal carcinoma.Cell death & disease · 2019Article
- Glucosamine Enhances TRAIL-Induced Apoptosis in the Prostate Cancer Cell Line DU145.Medicines (Basel, Switzerland) · 2019Article
Corrections and comments
- Correction · 2021-08-31Duplication of/in Image · · see also: https://www.nytimes.com/2017/03/08/science/cancer-carlo-croce.html?hp&action=click&pgtype=Homepage&clickSource=image&module=photo-spot-region®ion=top-news&WT.nav=top-news&_r=2
- Correction · 2017-03-13Concerns/Issues about Referencing/Attributions · Duplication of Text · Euphemisms for Plagiarism · Investigation by Company/Institution · Objections by Third Party · Plagiarism of Text · · see also: https://www.nytimes.com/2017/03/08/science/cancer-carlo-croce.html?hp&action=click&pgtype=Homepage&clickSource=image&module=photo-spot-region®ion=top-news&WT.nav=top-news&_r=2
- Erratum issued
- Erratum issued
Authors and funding
18 authors at 6 institutions in 4 countries.
Funding
Abstract
TRAIL (TNF-related apoptosis-inducing ligand) is a promising anticancer agent that can be potentially used as an alternative or complementary therapy because of its specific antitumor activity. However, TRAIL can also stimulate the proliferation of cancer cells through the activation of NF-κB, but the exact mechanism is still poorly understood. In this study, we show that chronic exposure to subtoxic concentrations of TRAIL results in acquired resistance. This resistance is associated with the increase in miR-21, miR-30c, and miR-100 expression, which target tumor-suppressor genes fundamental in the response to TRAIL. Importantly, down-regulation of caspase-8 by miR-21 blocks receptor interacting protein-1 cleavage and induces the activation of NF-κB, which regulates these miRNAs. Thus, TRAIL activates a positive feedback loop that sustains the acquired resistance and causes an aggressive phenotype. Finally, we prove that combinatory treatment of NF-κB inhibitors and TRAIL is able to revert resistance and reduce tumor growth, with important consequences for the clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.